OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 …,

First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, …, First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, …, Read More

Scroll to Top